Patents by Inventor Jian Guo Zhang
Jian Guo Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150265721Abstract: The present invention relates to the identification of proteins which bind the dendritic cell marker known as Clec9A. The present invention provides new compounds for targeting therapeutic agents such as antigens to dendritic cells. Also provided are methods of modulating a humoral and/or T cell mediated immune response to the antigen, methods of delivery of a cytotoxic agent to dendritic cells thereof involved in diseased states, methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, and methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.Type: ApplicationFiled: December 23, 2014Publication date: September 24, 2015Inventors: Mireille Hanna Lahoud, Irina Caminschi, Ken Shortman, Jian-Guo Zhang, Mark Francis Van Delft, David Ching Siang Huang, Nicos Anthony Nicola, Alan Frederick Cowman, Mark Dexter Wright
-
Publication number: 20140335104Abstract: The present invention relates to methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, which can be used to treat and/or prevent diseases such as cancer, autoimmunity and infections. The present invention also relates to methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof. The present invention further relates to methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.Type: ApplicationFiled: April 14, 2014Publication date: November 13, 2014Inventors: Mireille Hanna Lahoud, Irina Caminschi, Ken Shortman, Jian-Guo Zhang, Mark Francis Van Delft, David Ching Siang Huang, Mark Dexter Wright
-
Publication number: 20120039806Abstract: The present invention relates to the identification of proteins which bind the dendritic cell marker known as Clec9A. The present invention provides new compounds for targeting therapeutic agents such as antigens to dendritic cells. Also provided are methods of modulating a humoral and/or T cell mediated immune response to the antigen, methods of delivery of a cytotoxic agent to dendritic cells thereof involved in diseased states, methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, and methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.Type: ApplicationFiled: March 22, 2010Publication date: February 16, 2012Inventors: Mireille Hanna Lahoud, Irina Caminschi, Jian-Guo Zhang, Mark Francis Van Delft, David Ching Siang Huang, Nicos Anthony NIcola, Alan Cowman, Mark Dexter Wright
-
Publication number: 20110110861Abstract: The present invention relates to methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, which can be used to treat and/or prevent diseases such as cancer, autoimmunity and infections. The present invention also relates to methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof. The present invention further relates to methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.Type: ApplicationFiled: May 1, 2009Publication date: May 12, 2011Inventors: Mireille Hanna Lahoud, Irina Caminschi, Ken Shortman, Jian-Guo Zhang, Mark Francis Van Delft, David Ching Siang Huang, Mark Dexter Wright
-
Publication number: 20080274973Abstract: The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: July 1, 2008Publication date: November 6, 2008Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Patent number: 7256007Abstract: The present invention relates generally to a method for regulating cytokine signaling and agents useful for same. The method of the present invention is predicated in part on the identification of the molecular target of suppressor of cytokine signaling (SOCS) interaction in controlling cytokine signaling. The identification of the molecular target permits the development of assays to screen for a range of agonists and antagonists useful in modulating cytokine function. The present invention further provides, therefore, screening assays and more particularly high through-put screening assays for agonists and antagonists of SOCS-receptor interaction. Such agonists and antagonists are useful in the manufacture of medicaments for controlling cytokine signaling. Control of cytokine signaling is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders and any other conditions involving aberrations of signal transduction.Type: GrantFiled: March 9, 2001Date of Patent: August 14, 2007Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Sandra Elaine Nicholson, Manuel Baca, Nicos A. Nicola, Douglas Hilton, Jian Guo Zhang, Louis Fabri, Andrew Nash
-
Patent number: 7220828Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: GrantFiled: March 10, 1998Date of Patent: May 22, 2007Assignee: Zenyth Operations Pty LtdInventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Jian-Guo Zhang, Alison Farley, Warren Alexander, Steven Rakar, Yasufumi Kikuchi, Tetsuo Kojima, Masatsugu Maeda, Louis Fabri, Andrew Nash
-
Publication number: 20060294608Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: August 24, 2006Publication date: December 28, 2006Applicant: Zenyth Operations Pty LtdInventors: Douglas Hilton, Nicos Nicola, Alison Farley, Tracy Willson, Jian-Guo Zhang, Warren Alexander, Steven Rakar, Louis Fabri, Tetsuo Kojima, Masatsugu Maeda, Yasufumi Kikuchi, Andrew Nash
-
Patent number: 7078174Abstract: The present invention relates generally to amino acid sequences obtainable from SOCS proteins and which are capable of interacting with intracellular molecules. The present invention further relates to nucleic acid molecules encoding said amino acid sequences. The amino acid sequences and the nucleic acid molecules encoding same of the present invention are useful in modulating degradation of proteinaceous molecules such as but not limited to SOCS proteins and proteinaceous molecules associated therewith. The present invention provides a mechanism for modulating cytokine or cytokine-like molecule signalling by modulating the degradation of activated signal transduction molecules or their negative regulators, i.e. the SOCS proteins.Type: GrantFiled: December 21, 1999Date of Patent: July 18, 2006Assignee: The Walter & Eliza Hall Institute of Medical ResearchInventors: Tracy Ann Willson, Richard John Simpson, Alison Mary Farley, Sandra Elaine Nicholson, Jian-Guo Zhang, Manuel Baca, Nicos A. Nicola, Douglas J. Hilton, Warren Scott Alexander, Donald Metcalf
-
Patent number: 6958303Abstract: The invention provides partially stabilised zirconia and alumina based electro-static dissipative or ESD ceramic compositions. The proposed ceramic compositions include specific amounts of dopants comprising one or more metal oxides selected from iron oxide, chromium oxide and titanium oxide. The proposed ESD ceramic materials are made into useful industrial products by injection moulding and sintering technology. A novel binder system may optionally be used to make injection mouldable feedstock. Useful products produced by the invention include, for example, ESD ceramic tweezers tips, ESD ceramic dispensing needles, ESD ceramic scissors and blades and ESD ceramic wire bonding capillaries which retain their ESD properties at relatively low temperatures, for example, service temperatures from 25 to 500° C.Type: GrantFiled: May 30, 2003Date of Patent: October 25, 2005Assignee: Dou Yee Technologies Pte Ltd.Inventors: Jian Guo Zhang, Hwey Eng Liow, Bo Zhang
-
Patent number: 6911530Abstract: The present invention relates generally to a novel haemopoietin receptor or components or part thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: GrantFiled: October 13, 2000Date of Patent: June 28, 2005Assignee: Amrad Operations, Pty., Ltd.Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Publication number: 20040242401Abstract: The invention provides partially stabilised zirconia and alumina based electro-static dissipative or ESD ceramic compositions. The proposed ceramic compositions include specific amounts of dopants comprising one or more metal oxides selected from iron oxide, chromium oxide and titanium oxide. The proposed ESD ceramic materials are made into useful industrial products by injection moulding and sintering technology. A novel binder system may optionally be used to make injection mouldable feedstock. Useful products produced by the invention include, for example, ESD ceramic tweezers tips, ESD ceramic dispensing needles, ESD ceramic scissors and blades and ESD ceramic wire bonding capillaries which retain their ESD properties at relatively low temperatures, for example, service temperatures from 25 to 500° C.Type: ApplicationFiled: May 30, 2003Publication date: December 2, 2004Applicant: Dou Yee Technologies PTE, LTD.Inventors: Jian Guo Zhang, Hwey Eng Liow, Bo Zhang
-
Publication number: 20030191058Abstract: The present invention relates generally to a method for regulating cytokine signalling and agents useful for same. The method of the present invention is predicated in part on the identification of the molecular target of suppressor of cytokine signalling (SOCS) interaction in controlling cytokine signalling. The identification of the molecular target permits the development of assays to screen for a range of agonists and antagonists useful in modulating cytokine function. The present invention further provides, therefore, screening assays and more particularly high through-put screening assays for agonists and antagonists of SOCS-receptor interaction. Such agonists and antagonists are useful in the manufacture of medicaments for controlling cytokine signalling. Control of cytokine signalling is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders and any other conditions involving aberrations of signal transduction.Type: ApplicationFiled: February 19, 2003Publication date: October 9, 2003Inventors: Sandra Elaine Nicholson, Manuel Baca, Nicos A Nicola, Douglas Hilton, Jian Guo Zhang, Louis Fabri, Andrew Nash
-
Publication number: 20020090682Abstract: The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: November 7, 2001Publication date: July 11, 2002Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Publication number: 20020045741Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: March 10, 1998Publication date: April 18, 2002Inventors: TRACY WILLSON, NICOS A. NICOLA, DOUGLAS J. HILTON, DONALD METCALF, JIAN GUO ZHANG